PMC President: ICER 'Has a Responsibility' to Provide Adequate Time for Public Comment
WASHINGTON (July 1, 2016)
The Personalized Medicine Coalition (PMC) today commends the Institute for Clinical and Economic Review (ICER) for providing an additional week for public comments on a document related to the scope of ICER's work in non-small cell lung cancer (NSCLC).
ICER announced the extension three days after PMC joined other stakeholders in expressing concern about the organization's comment timelines. After meeting with ICER Director of Health Economics Rick Chapman, Ph.D., during a PMC policy committee meeting last week, the Coalition suggested that ICER provide a 30 - 60 day window for public comments.
"Given the significant attention ICER's assessments receive and the recent proposal by CMS to rely on ICER's value standards in the Part B payment demonstration, we believe ICER has a responsibility to allow additional time for stakeholders to provide thorough, thoughtful feedback on the scoping document as well as the draft evidence report," PMC President Edward Abrahams wrote in a comment letter on ICER's draft scoping document for NSCLC.
Abrahams noted in PMC's letter to ICER that federal agencies like FDA and CMS typically provide 30 - 60 days for public comments on significant policy documents. ICER's doing so would give PMC and other organizations enough time to evaluate how its value assessments might impact personalized medicine, which is the focus of President Obama's Precision Medicine Initiative and a key aspect of Vice President Biden's Cancer Moonshot Task Force.
In a blog posted yesterday morning, PMC Executive Vice President Amy M. Miller, Ph.D., said PMC looks forward to continuing its engagement with ICER.
"Because ICER plays a unique role in health policy, with health plans being the primary audience for their work, PMC will suggest improvements to ICER’s system to ensure that resulting work accounts for the challenges involved in assessing value of treatments that work for specific subgroups of patients,” Miller wrote.
Christopher J. Wells
About the Personalized Medicine Coalition:
The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. For more information about PMC, please visit www.personalizedmedicinecoalition.org.